首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi

市場調查報告書

商品編碼

1396658

mRNA：各種藥品和世界市場

mRNA: Therapeutics and Global Markets

出版日期: 2023年12月13日 | 出版商:

BCC Research | 英文 171 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球 mRNA 藥物市場規模預計將從 2023 年的 330 億美元下降到年終的210 億美元，預測期內年複合成長率為 -8.6%。

新冠疫苗部門預計將從 2023 年的 330 億美元下降到 2028 年的 169 億美元，年複合成長率為-12.5%。同時，非新冠病毒藥物和疫苗部門預計到 2025 年將成長至 5.6 億美元，到 2028 年將成長至 41 億美元，預測期內年複合成長率為 94.7%。

本報告調查了全球mRNA 藥物市場，並按各個細分市場和地區提供了市場和藥物的概述和背景、市場影響因素和市場機會、目標疾病和病症、市場規模趨勢和預測的分析。它總結了詳細資訊主要企業的技術和專利趨勢、競爭形勢和概況分析。

RNA醫學的演變
RNA醫學的歷史
RNA藥物及其類型的開發
DNA藥物與RNA藥物
RNA藥物的臨床需求
患病人數增加和經濟負擔增加
傳統藥物的局限性
生技藥品的治療局限性
慢性病管理不善
罕見疾病治療有限
RNA醫學
反義寡核苷酸 (ASO) 作為藥物
小干擾 RNA (siRNA) 作為藥物
miRNA作為藥物
適體作為藥物
mRNA作為藥物
製造基於 RNA 的生物製藥
層析法精製程式
提供RNA藥品
聚合物鍵結/化學改性
封裝
脂質奈米粒子
高分子奈米材料
二氧化矽奈米粒子
碳和金奈米材料
GalNAc
設施和醫院的 RNA 藥物
法規對 RNA 藥品市場的影響
COVID-19 的影響

第4章市場動態

市場動態
促進因素
抑制因素
機會

第5章目標疾病與病症

mRNA 藥物常見疾病和病症概述
癌症
感染疾病
循環系統疾病
文明病
呼吸系統疾病
肌肉骨骼疾病
胃腸道疾病
泌尿系統疾病
腎臟疾病
免疫疾病
神經系統疾病
罕見疾病
其他疾病
吸煙與相關疾病
感染疾病：COVID-19 大流行和 mRNA 藥物
慢性病：擴大 mRNA 藥物的視野
罕見疾病中未滿足的需求：mRNA 藥物
老化、性別和疾病發生
世界人口統計
美國人口統計
歐洲人口統計
日本人口統計

第6章研發管線和臨床試驗分析

mRNA疫苗
mRNA醫學
臨床試驗分析

第7章市場區隔：依產品

mRNA COVID 疫苗的作用機制
三種最先進的mRNA疫苗

第8章市場細分：按地區

北美洲
加拿大
歐洲
亞太地區
日本
韓國
中國
印度
澳洲
其他地區

第9章新技術與新進展

概述
奈米粒子
修飾的mRNA
mRNA自動合成套件
生物平台

第10章專利分析

專利分析
mRNA應用發表

第11章併購與資金籌措

第12章競爭資訊

第13章公司簡介

ARCTUR US THERAPEUTICS INC.
BIONTECH SE
CUREVAC NV
GENNOVA BIOPHARMACEUTICALS LTD.
MERCK KGAA
MODERNA INC.
NUTCRACKER THERAPEUTICS
OMEGA THERAPEUTICS INC.
STRAND THERAPEUTICS
VAXESS TECHNOLOGIES INC.

簡介目錄圖表

Product Code: BIO212B

Highlights:

The global market for mRNA therapeutics is expected to decline from $33 billion in 2023 to $21 billion by the end of 2028, at a compound annual growth rate (CAGR) of -8.6% during the forecast period of 2023-2028.

The COVID vaccines segment of the mRNA therapeutics market is expected to decline from $33 billion in 2023 to $16.9 billion by 2028, at a CAGR of -12.5% during the forecast period of 2023-2028.

The non-COVID therapeutics and vaccines segment of the mRNA therapeutics market is expected to grow from $560 million in 2025 to $4.1 billion by 2028, at a CAGR of 94.7% during the forecast period of 2023-2028.

Report Scope:

This report focuses on the mRNA therapeutics market. This reports include the types of mRNA and their application in therapy. Also, the report focuses on the patent analysis and clinical trial analysis of mRNA. The report also portrays the trends and dynamics affecting the market during the study period. The study covers market projections through 2028 and profiles major market players.

By geography, the market is segregated into North America, Europe, Asia-Pacific and the Rest of the World (RoW). The market is estimated through 2028.

BCC Research also summarizes the main industry acquisitions and strategic alliances from January 2020 through December 2022 and identifies the trends in this activity.

Report Includes:

37 data tables and 27 additional tables
An overview of the global market related to mRNA therapeutics
In-depth analysis of global market trends, featuring historical revenue data for 2021 and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028
Evaluation of the current market and revenue growth prospects specific to mRNA therapeutics, accompanied by a market share analysis by therapeutic type and geographical region
Coverage of the pandemic threats, therapeutic developments, and new technologies in the market
Discussion of the advantages of mRNA over protein- and DNA-based delivery systems, demographic and economic trends, and outlook for the mRNA therapeutics market
Information on prophylactic vaccines, vaccine discovery and development, and R&D activities
Analysis of the various therapeutics as well as promising vaccines intended for the prevention and treatment of chronic and infectious diseases
Assessment of regulatory structure, pricing and reimbursement scenarios, the pipeline for new molecules and therapeutics
Market share analysis of the key companies and mergers & acquisitions, joint ventures, collaborations, and partnerships
Profiles of leading market participants

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in This Update?
Methodology
Information Sources
Geographic Breakdown
Segmentation Breakdown

Chapter 2 Summary and Highlights

Market Outlook
Market Summary

Chapter 3 Market Overview

Evolution of RNA Therapeutics
History of RNA Therapeutics
Development of RNA Therapeutics and Types
DNA Therapeutics vs. RNA Therapeutics
Clinical Need for RNA Therapeutics
Increasing Disease Population and Economic Burden
Limitations of Traditional Therapeutics
Therapeutic Limitations of Biologics
Poor Management of Chronic Diseases
Limited Treatment for Rare Diseases
RNA Therapeutics
Antisense Oligonucleotide (ASO) as Therapeutics
Small Interfering RNA (siRNA) as Therapeutics
miRNA as Therapeutics
Aptamers as Therapeutics
mRNA as Therapeutics
Manufacturing RNA-Based Biopharmaceuticals
Chromatographic Purification Steps
Delivery of RNA Therapeutics
Polymer Conjugation/Chemical Modification
Encapsulation
Lipid-Based Nanoparticles
Polymer Nanomaterials
Silica Nanoparticles
Carbon and Gold Nanomaterials
GalNAc
Institution and Hospital-Based RNA Therapeutics
Regulatory Influence on the Market for RNA Therapeutics
Impact of COVID-19

Chapter 4 Market Dynamics

Market Dynamics
Drivers
Restraints
Opportunities

Chapter 5 Target Disease and Disorders

Overview of Common Diseases and Disorders for mRNA Therapeutics
Cancer
Infectious Diseases
Cardiovascular Disease
Lifestyle Disorders
Respiratory Disorders
Musculoskeletal Disorders
Gastrointestinal Disorders
Urology Disorders
Nephrology Disorders
Immune Disorders
Neurological Disorders
Rare Diseases
Other Disorders
Tobacco Smoking and Associated Diseases
Infectious Diseases: COVID-19 Pandemic and mRNA Therapeutics
Chronic Diseases: Expanding Horizon for mRNA Therapeutics
Unmet Needs of Rare Diseases: mRNA Therapeutics
Aging, Gender and Onset of Diseases
Global Demographics
U.S. Demographics
European Demographics
Japanese Demographics

Chapter 6 Pipeline and Clinical Trial Analysis

mRNA Vaccines
mRNA Therapeutics
Clinical Trial Analysis

Chapter 7 Market Breakdown by Product

Mechanism of Action of mRNA COVID Vaccines
Three Most-Advanced mRNA Vaccines

Chapter 8 Market Breakdown by Region

North America
Canada
Europe
Asia-Pacific
Japan
South Korea
China
India
Australia
RoW

Chapter 9 Emerging Technologies and Developments

Overview
Nanoparticles
Modified mRNA
Automated mRNA Synthesis Kits
Bio Platforms

Chapter 10 Patent Analysis

Patent Analysis
mRNA Publication

Chapter 11 Outlook for Mergers & Acquisitions, and Venture Funding

Chapter 12 Competitive Intelligence

Chapter 13 Company Profiles

ARCTUR U.S. THERAPEUTICS INC.
BIONTECH SE
CUREVAC N.V.
GENNOVA BIOPHARMACEUTICALS LTD.
MERCK KGAA
MODERNA INC.
NUTCRACKER THERAPEUTICS
OMEGA THERAPEUTICS INC.
STRAND THERAPEUTICS
VAXESS TECHNOLOGIES INC.

簡介目錄圖表

List of Tables

Summary Table : Global Market for mRNA Therapeutics, by Type, Through 2028
Table 1 : COVID-19: Total Cases and Deaths, by Select Country, 2023
Table 2 : Pandemics of the 21st Century
Table 3 : Global Prevalence of Breast Cancer Cases, by Country/Region, Through 2025
Table 4 : Global Epidemiology of Colorectal Cancer Cases, by Region, Through 2030
Table 5 : Global Cancer-Related Deaths, by Cancer Type, Through 2030
Table 6 : Distribution of Global Cancer-Related Deaths, by Cancer Type, 2022
Table 7 : Case Fatality Rate, Global Viral Outbreaks, 2020
Table 8 : Global Incidence Share of Hypertension, by Patient Group Type, 2020
Table 9 : Global Prevalence of Angina Pectoris and Stroke (Survivors), Through 2030
Table 10 : Global Prevalence of CHF and Stroke, Through 2030
Table 11 : Structural Heart Disease Management Through Medications
Table 12 : BMI Categories Based on Increasing Health Risks
Table 13 : Trends in Obesity Composition of the Global Population, Through 2025
Table 14 : Obesity and Severe Obesity vs. General Population in the U.S., Through 2025
Table 15 : Global Distribution of Diabetes, by Type
Table 16 : Global Prevalence of Diabetes, by Type, Through 2040
Table 17 : Global Prevalence of Key Symptomatic Musculoskeletal Disorders, Through 2025
Table 18 : Global Deaths, by Type of Musculoskeletal Disorder, Through 2030
Table 19 : Global Deaths from Digestive Diseases, by Region, Through 2025
Table 20 : Global Distribution of Mortality, by Chronic Disease Type, 2019
Table 21 : Global Distribution of DALYs, by Chronic Disease Type, 2019
Table 22 : Estimated World Population and Annual Growth, by Age Group, Through 2030
Table 23 : Total Global Population, by Select Country/Region, Through 2030
Table 24 : U.S. Population Projections and Estimates, by Age Group, Through 2030
Table 25 : Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, Through 2020
Table 26 : European Population Estimates and Projections, by Age Group, Through 2030
Table 27 : Japanese Population Estimates and Projections, by Age Group, Through 2030
Table 28 : Clinical Trials on mRNA Vaccine Candidates, 2023
Table 29 : Clinical Trials on mRNA Vaccine Candidates for Cancer Treatments, as of 2023
Table 30 : Clinical Trials on mRNA Therapeutic Application
Table 31 : Properties of BNT162b2 Vaccine
Table 32 : Properties of mRNA-1273 Vaccine
Table 33 : Properties of CVnCoV Vaccine
Table 34 : Global Market for COVID Vaccines, by Region, Through 2028
Table 35 : Global Market for Non-COVID mRNA Therapeutics, by Region, Through 2028
Table 36 : Global Market for mRNA Therapeutics, by Region, Through 2028
Table 37 : North American Market for mRNA Therapeutics, by Type, Through 2028
Table 38 : European Market for mRNA Therapeutics, by Type, Through 2028
Table 39 : Asia-Pacific Market for mRNA Therapeutics, by Type, Through 2028
Table 40 : RoW Market for mRNA Therapeutics, by Type, Through 2028
Table 41 : mRNA Patents: Top 10 Organizations
Table 42 : Notable Patents for mRNA Therapeutics
Table 43 : Some of the Notable Patents Related to mRNA Vaccines for Infectious Diseases
Table 44 : Some of the Notable Patents Related to mRNA Vaccines for Cancer
Table 45 : Notable Patents Focused on mRNA Delivery and Modification
Table 46 : Recent M&A Deals on mRNA Therapeutics Company, 2006-2021
Table 47 : Major Development of Company Profiles, 2021-2023
Table 48 : BioNTech: Annual Revenue, 2021 and 2022
Table 49 : BioNTech: News, 2021-2023
Table 50 : BioNTech: ESG Developments, 2021
Table 51 : BioNTech: Pipeline Products
Table 52 : CureVac: Annual Revenue, 2021 and 2022
Table 53 : CureVac: News, 2021-2023
Table 54 : CureVac: Pipeline
Table 55 : Merck: Annual Revenue, 2021 and 2022
Table 56 : Merck: miRNA Product Portfolio
Table 57 : Merck: Key Developments, Jan 2021-May 2023
Table 58 : Moderna Inc.: Annual Revenue, 2021 and 2022
Table 59 : Moderna Inc.: News, 2021-2023
Table 60 : Moderna Inc.: Pipeline Products
Table 61 : Nutcracker Therapeutics: Pipeline Products
Table 62 : Strand Therapeutics: Pipeline Products
Table 63 : Strand Therapeutics: News, 2021-2023

List of Figures

Summary Figure : Global Market for mRNA Therapeutics, by Type, 2021-2028
Figure 1 : Development Timeline: COVID-19 mRNA Vaccines
Figure 2 : Reasons for Increasing Pandemics
Figure 3 : Benefits of Vaccination
Figure 4 : Investment in RNA Therapeutics 2011 to 2021
Figure 5 : Global Prevalence of Breast Cancer Cases, by Region/Country, 2015-2025
Figure 6 : Global Cancer-Related Deaths, by Cancer Type, 2000-2030
Figure 7 : Distribution of Global Cancer-Related Deaths, by Cancer Type, 2022
Figure 8 : Case Fatality Rate Share, Global Viral Outbreaks, 2020
Figure 9 : Global Incidence Share of Hypertension, by Patient Group Type, 2020
Figure 10 : Global Prevalence of Angina Pectoris and Stroke (Survivors), 2004-2030
Figure 11 : Global Prevalence of CHF and Stroke, 2004-2030
Figure 12 : Trends in Obesity Composition of the Global Population, 2012-2025
Figure 13 : Obesity and Severe Obesity vs. General Population in the U.S., 2018 and 2025
Figure 14 : Global Distribution of Diabetes, by Type
Figure 15 : Global Prevalence of Diabetes, by Type, 2018 and 2040
Figure 16 : Global Prevalence of Key Symptomatic Musculoskeletal Disorders, 2012-2025
Figure 17 : Global Deaths, by Type of Musculoskeletal Disorder, 2000-2030
Figure 18 : Global Distribution of Mortality, by Chronic Disease Type, 2019
Figure 19 : Global Distribution of DALYs, by Chronic Disease Type, 2019
Figure 20 : Estimated World Population and Annual Growth, by Age Group, 2000-2030
Figure 21 : Total Global Population, by Select Country/Region, 2000-2030
Figure 22 : U.S. Population Estimates and Projections, by Age Group, 2000-2030
Figure 23 : Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, 2005-2020
Figure 24 : European Population Estimates and Projections, by Age Group, 2000-2030
Figure 25 : Japanese Population Estimates and Projections, by Age Group, 2000-2030
Figure 26 : Distribution of Clinical Trials on mRNA Vaccines, by Disease Indication, 2023
Figure 27 : Distribution of mRNA Vaccine Candidates in Clinical Trials, by Phase, 2023
Figure 28 : Distribution of mRNA Vaccine Candidates in Clinical Trials, by Mode of Administration, 2023
Figure 29 : Clinical Trials on mRNA Therapeutics, Based on Recruiting Status, January 2020 to October 2023
Figure 30 : Share of Clinical Trials on mRNA Therapeutics, With or Without Results, January 2020 to October 2023
Figure 31 : Clinical Trials on mRNA Therapeutics, Based on Age Group, January 2020 to October 2023
Figure 32 : Share of Clinical Trials on mRNA Therapeutics, Based on Gender, January 2020 to October 2023
Figure 33 : Share of Clinical Trials on mRNA Therapeutics, by Trial Phase, January 2020 to October 2023
Figure 34 : Share of Clinical Trials on mRNA Therapeutics, by Type of Funder, January 2020 to October 2023
Figure 35 : Share of Clinical Trials on mRNA Therapeutics, by Enrollment Number, January 2020 to October 2023
Figure 36 : Share of Clinical Trials on mRNA Therapeutics, by Interventional Mode, January 2020 to October 2023
Figure 37 : Share of Clinical Trials on mRNA Therapeutics, by Type, January 2020 to October 2023
Figure 38 : Global Market for mRNA Therapeutics, 2021-2028
Figure 39 : Innovations in mRNA Therapeutics
Figure 40 : mRNA Based Patent Publications, 2019-2021
Figure 41 : Patents on mRNA Therapeutics, 2010-2021
Figure 42 : Share of Patents on mRNA Therapeutics, by Patent Classification, 2010 to 2021
Figure 43 : Funding in the mRNA Market, by Various Sources, 2021-2023
Figure 44 : Top Three Companies: mRNA Vaccines and Therapeutics
Figure 45 : Share of Key Growth Strategies of Major Companies, 2021-2023
Figure 46 : BioNTech: Annual Revenue, 2021 and 2022
Figure 47 : CureVac: Annual Revenue, 2020 and 2021
Figure 48 : Merck: Annual Revenue, 2021 and 2022
Figure 49 : Merck: Market Share, by Business Segment, 2022
Figure 50 : Merck: Revenue Share, by Region, 2022
Figure 51 : Moderna Inc.: Annual Revenue, 2021 and 2022
Figure 52 : Moderna Inc.: Revenue Share, by Segment, 2022